Immunovia AB (publ) (IMMNOV.ST)
SEK 0.66
(1.23%)
SEK 0.66
(1.23%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -296.46 Million SEK | -55.09% |
| 2022 | -191.15 Million SEK | -14.64% |
| 2021 | -166.74 Million SEK | -23.81% |
| 2020 | -134.67 Million SEK | -17.78% |
| 2019 | -114.35 Million SEK | -30.37% |
| 2018 | -87.7 Million SEK | -92.68% |
| 2017 | -45.51 Million SEK | -203.91% |
| 2016 | -14.97 Million SEK | -101.75% |
| 2015 | -7.42 Million SEK | 17.14% |
| 2014 | -8.95 Million SEK | -455.23% |
| 2013 | -1.61 Million SEK | -495.87% |
| 2012 | -270.8 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -24.15 Million SEK | -3.21% |
| 2024 Q2 | -23.97 Million SEK | 1.03% |
| 2023 FY | -296.46 Million SEK | -55.09% |
| 2023 Q2 | -185.07 Million SEK | -277.07% |
| 2023 Q1 | -49.08 Million SEK | 3.91% |
| 2023 Q3 | -38.88 Million SEK | 78.99% |
| 2023 Q4 | -23.4 Million SEK | 39.81% |
| 2022 Q3 | -41.91 Million SEK | 17.47% |
| 2022 FY | -191.15 Million SEK | -14.64% |
| 2022 Q4 | -51.08 Million SEK | -21.86% |
| 2022 Q2 | -50.78 Million SEK | -7.22% |
| 2022 Q1 | -47.36 Million SEK | 6.9% |
| 2021 Q3 | -39.93 Million SEK | 14.54% |
| 2021 Q1 | -29.08 Million SEK | 23.69% |
| 2021 Q2 | -46.73 Million SEK | -60.69% |
| 2021 FY | -166.74 Million SEK | -23.81% |
| 2021 Q4 | -50.87 Million SEK | -27.39% |
| 2020 FY | -134.67 Million SEK | -17.78% |
| 2020 Q1 | -32.11 Million SEK | -8.56% |
| 2020 Q2 | -28.68 Million SEK | 10.67% |
| 2020 Q4 | -38.11 Million SEK | -7.56% |
| 2020 Q3 | -35.43 Million SEK | -23.52% |
| 2019 Q2 | -29.54 Million SEK | -8.62% |
| 2019 Q4 | -29.58 Million SEK | -5.93% |
| 2019 Q1 | -27.19 Million SEK | -5.59% |
| 2019 FY | -114.35 Million SEK | -30.37% |
| 2019 Q3 | -27.92 Million SEK | 5.47% |
| 2018 FY | -87.7 Million SEK | -92.68% |
| 2018 Q4 | -25.75 Million SEK | -48.51% |
| 2018 Q3 | -17.34 Million SEK | 36.31% |
| 2018 Q1 | -17.37 Million SEK | -13.11% |
| 2018 Q2 | -27.23 Million SEK | -56.71% |
| 2017 Q1 | -7.87 Million SEK | -42.39% |
| 2017 FY | -45.51 Million SEK | -203.91% |
| 2017 Q4 | -15.36 Million SEK | -31.97% |
| 2017 Q3 | -11.64 Million SEK | -9.36% |
| 2017 Q2 | -10.64 Million SEK | -35.26% |
| 2016 Q3 | -4.04 Million SEK | -36.43% |
| 2016 Q4 | -5.52 Million SEK | -36.54% |
| 2016 FY | -14.97 Million SEK | -101.75% |
| 2016 Q2 | -2.96 Million SEK | -21.85% |
| 2016 Q1 | -2.43 Million SEK | -35.72% |
| 2015 FY | -7.42 Million SEK | 17.14% |
| 2015 Q4 | -1.79 Million SEK | 0.0% |
| 2015 Q1 | -1.91 Million SEK | 37.36% |
| 2015 Q3 | -1.79 Million SEK | 6.46% |
| 2015 Q2 | -1.91 Million SEK | 0.0% |
| 2014 Q4 | -3.06 Million SEK | 0.0% |
| 2014 Q1 | -1.41 Million SEK | 0.0% |
| 2014 Q2 | -1.41 Million SEK | 0.0% |
| 2014 Q3 | -3.06 Million SEK | -115.93% |
| 2014 FY | -8.95 Million SEK | -455.23% |
| 2013 FY | -1.61 Million SEK | -495.87% |
| 2012 FY | -270.8 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AroCell AB (publ) | -59.78 Million SEK | -395.885% |
| Devyser Diagnostics AB (publ) | -56.5 Million SEK | -424.708% |
| Prostatype Genomics AB (publ) | -39.3 Million SEK | -654.236% |
| SenzaGen AB | -14.74 Million SEK | -1911.262% |
| Spermosens AB | -10.89 Million SEK | -2621.314% |